Tag - CLSD

Feature

Arctic Vision sees busy ophthalmic business development in 2021

After closing four licensing deals for five assets in 2020 and so far in 2021, including its latest deal in early June, closely-held Arctic Vision, a leading player in China’s ophthalmology market, has no plans to slow...

June 22, 2021

Developments

Clearside Biomedical posts positive safety results in Phase 1/2a wet AMD study

Clearside Biomedical (NASDAQ:CLSD) reported positive safety results from Cohort 1 of OASIS, its ongoing Phase 1/2a clinical trial of CLS-AX, an axitinib injectable suspension, which is administered by suprachoroidal...

June 15, 2021

Developments

Ophthalmology publishes Bausch, Clearside pivotal XIPERE data

Ophthalmology, the peer-reviewed journal of the American Academy of Ophthalmology, published results of a Phase 3 clinical trial by Bausch Health Companies (NYSE, TSX:BHC) and Clearside Biomedical (NASDAQ:CLSD) of...

January 28, 2020

Tag - CLSD

Arctic Vision sees busy ophthalmic business development in 2021

Clearside Biomedical posts positive safety results in Phase 1/2a wet AMD study

Ophthalmology publishes Bausch, Clearside pivotal XIPERE data

General

More